PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.\', \'School of Biological Sciences, University of Southampton, Southampton, UK.\', \'Department of Biochemistry, Oxford Glycobiology Institute, University of Oxford, Oxford, UK.\', \'Binding Site Group Ltd, Birmingham, UK.\', \'Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.\', \'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.\', \'Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, Birmingham, UK.\', \'Immunodeficiency Centre for Wales, Cardiff, UK.\', \'Department of Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1111/imm.13349
?:hasPublicationType
?:journal
  • Immunology
is ?:pmid of
?:pmid
?:pmid
  • 33932228
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.69
?:rankingScore_hIndex
  • 115
is ?:relation_isRelatedTo_publication of
?:title
  • Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33932228>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33932228>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all